GRACEcast Bladder Cancer Video
Channel Details
GRACEcast Bladder Cancer Video
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to b...
Recent Episodes
300 episodes
Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
Management of Rare Kidney Tumors
What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient shoul...
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
NanoString Treatment for Kidney Cancer
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be m...
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical i...
How is the Heng Criteria Applied to Kidney Cancer Patients?
Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had m...
What is PD1 and PDL1 in Kidney Cancer?
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney canc...
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side e...
No Clear Answer for Non-Clear Cell Kidney Cancer
Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperate...
What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer
"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetM...
Treating Newly Diagnosed Kidney Cancer
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
MET-Amplified Lung Cancer: A New Target for XALKORI?
Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
The Hottest Thing in Late Stage Kidney Cancer
Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.
CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side eff...
The Promise of PD1 Inhibitors in Kidney Cancer
Results from recent clinical trials looking into PD1 inhibitors of kidney cancer are giving patients and doctors reasons to be hopeful.
FGFR and Its Role in Treating Squamous Cell Lung Cancer
Fibroblast growth factor receptor (FGFR) mutations may play a role in the growth of squamous cell lung cancer. Dr. Jonathan Riess talks about what the...
AZD9291 for Acquired Resistance in EGFR Positive Lung Cancer
EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.
What Are Heat Shock Protein (HSP) 90 Inhibitors and How May They Help Fight Lung Cancer?
"HSP 90 inhibitors are a really cool class of drugs..." states Dr. Melissa Johnson of the Robert H. Lurie Comprehensive Cancer Center as she describes...
What Is Non-Clear Cell Kidney Cancer?
Among kidney cancer patients, the sub-type "non-clear cell" is the least common. As a result, not much research has been conducted on it.
Does Gilotrif Help EGFR Positive Lung Cancer Patients?
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
The Promise of Immunotherapy in Lung Cancer
Dr. Leena Gandhi of Dana-Farber Cancer Institute sees great potential in immune therapies for lung cancer. In this video, she expresses her hope and e...
Is Progression-Free Survival Meaningful?
Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate...
DDR2 Mutations in Squamous Cell Lung Cancer
A genetic mutation and a leukemia drug may provide new hope for patients with squamous cell lung cancer patients.
Does Adding Avastin to Tarceva Help EGFR Positive Lung Cancer Patients?
Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab...
What is FGFR, and Could It Be a Valuable Target for Patients with Lung Cancer?
Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung c...
How Do We Make EGFR Inhibitors Work Better for Patients
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute describes what research indicates may be more successful treatments for EGFR lung cancer patients.
TH 302: New Drug May Make Tumors Less Resistant to Treatment
Dr. Jonathan Goldman discusses a drug currently being studied that may make lung cancer tumors more susceptible to treatment. February 2014.
Should We Do Broad Sequencing of All Lung Tumors?
How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumor...
How Do the New ALK Inhibitor Drugs Compare to Xalkori (Crizotinib) for ALK+ Lung Cancer Patients?
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great pr...
Why Are Non-Mutated EGFR Genes Called "Wild Type?"
When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes a...
Teaching the Immune System to Attack Lung Cancer Tumors
Immune therapy, or immunotherapy, is one of the most exciting areas of lung cancer research. Dr. Jonathan Goldman of UCLA Jonsson Comprehensive Cancer...
Advice for Lung Cancer Patients: Know Thy Cancer
What should lung cancer patients know about their disease? Dr. Jonathan Riess argues that patients should understand what type of lung cancer they hav...
Is It Necessary for Early Stage Lung Cancer Patients to Get Molecular Testing for Their Tumors?
If you were diagnosed with early stage lung cancer, should you receive molecular testing on your tumor in order to get targeted therapy? Dr. Joel Neal...
Treating EGFR Patients After Tarceva Stops Working
Tarceva (erlotinib) has greatly helped EGFR positive lung cancer patients, but eventually it stops working. Dr. Jonathan Goldman of UCLA Jonsson Compr...
Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive Non-small Cell Lung Cancer?
Dr. Joel Neal of Stanford University Medical Center discusses the SELECT clinical trial which studied early stage non-small cell lung cancer patients...
An Update on ECOG 1505: Will Avastin (Bevacizumab) Become Standard Treatment for Early Stage Lung Cancer Patients?
Dr. Heather Wakelee of Stanford University Medical Center talks about how studies looking into Avastin (bevacizumab) for early stage lung cancer patie...
Targeted Treatment for Lung Cancer After Progression
Dr. Geoffrey Oxnard of Dana-Farber Cancer Institute discusses whether or not patients on targeted therapies, such as EGFR inhibitors, should stay on t...
Can Vaccines Fight Lung Cancer?
Dr. Charles Rudin of Memorial Sloan Kettering on the possibility of using vaccines to fight lung cancer. February 2014.
CO-1686, a Third Generation Drug for EGFR Positive Lung Cancer Patients
Dr. Heather Wakelee of Stanford University Medical Center talks about a drug still in development for EGFR lung cancer patients, CO-1686. February 201...